« Return to News | CROs/Service Providers

Invacare completes sale of medical supplies business to AssuraMed

Wednesday, January 23, 2013 10:56 AM

Invacare, an Elyria, Ohio-based manufacturer and distributor of home and long-term care medical products, has completed the sale of its Invacare Supply Group (ISG) medical supplies business to AssuraMed, a medical supply distributor based in Twinsburg, Ohio, for a purchase price of approximately $150.8 million in cash.

Invacare estimates net proceeds from the sale of approximately $146.6 million, net of expenses.

This transaction is consistent with Invacare's globalization strategy, allowing the company to focus on its core equipment product lines. In line with its prior announcement of the transaction, Invacare intends to use the proceeds from the sale to reduce debt outstanding under its revolving credit facility. Invacare expects that this will better position it to accelerate new product development with selective acquisitions after it has completed its previously announced quality systems remediation at its corporate and Taylor Street manufacturing facilities in Elyria, Ohio.

Invacare filed a Form 8-K containing unaudited pro forma condensed combined financial statements with the Securities and Exchange Commission on January 22, 2013, which will reflect the effects of the disposition of ISG.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.